Anti-CD26 Binding Proteins for Targeted Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective targeting of the CD26 protein, which is implicated in various pathological processes including inflammation, immune-mediated diseases, tumor growth, and metabolic disorders, limiting therapeutic options for these conditions.
Innovation Solution
Development of anti-CD26 antigen-binding domains, including specific CDR sequences, which can be incorporated into proteins, antibodies, or chimeric antigen receptors to target and modulate CD26 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used, then treatment is provided for general conditions, but effective targeting of CD26 protein is lacking
Solution Approach 1:
The patent introduces anti-CD26 antibodies as intermediary molecules that specifically bind to the CD26 protein on target cells. These antibodies serve as mediators between the therapeutic agent and the CD26 target, enabling precise targeting while maintaining therapeutic efficacy. The antibodies bridge the gap between general therapy and specific CD26-targeted treatment.
2Adaptability or versatility
If CD26 activity is not modulated, then existing treatment mechanisms remain simple, but therapeutic options for immune-mediated diseases and tumors are limited
Solution Approach 1:
The anti-CD26 antibodies are designed with multi-functional capabilities: they can block CD26 enzymatic activity, prevent CD26-mediated immune suppression, and recruit immune effector cells through Fc region interactions. This single molecular entity performs multiple therapeutic functions, expanding treatment options without proportionally increasing complexity.
3Reliability
If CD26-mediated immune suppression is not blocked, then immune cell function remains unenhanced, but treatment of tumors and inflammatory diseases is ineffective
Solution Approach 1:
The patent converts the harmful CD26-mediated immune suppression into a beneficial therapeutic effect. By targeting CD26 with antibodies, the treatment exploits the CD26-adenosine pathway that normally suppresses immunity, and blocks it to enhance immune cell function. The same molecular interaction that causes suppression is targeted to eliminate the suppression and activate immune responses against tumors and inflammatory diseases.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-CD26 proteins enhance therapeutic efficacy by modulating CD26 activity, offering potential treatments for age-related diseases, inflammatory diseases, and cancers by enhancing immune cell function and reducing tumor growth.
Implementation Method 1
anti-CD26 antigen-binding domains, including specific CDR sequences, which can be incorporated into proteins, antibodies, or chimeric antigen receptors to target and modulate CD26 activity
Data Source
AI summary
Provided herein are proteins comprising an anti-CD26 antigen-binding domain. Also provided herein are methods of treating an aging-related disease or an inflammatory disease in a subject that include administering to the subject one of these proteins or a cell expressing one of these proteins.